The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Is autologous transplantation still relevant in DLBCL in the CAR-T era?
Leyre Bento De Miguel, MD, Son Espases University Hospital, Palma de Mallorca, Spain, discusses the relevance of autologous stem cell transplantation in diffuse large B-cell lymphoma (DLBCL) in the modern therapeutic era, highlighting that it can still play a role in some patients and in countries with limited access to CAR T-cell therapy. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in this last EBMT, we had a really interesting educational session focusing on the current role of transplant in large B-cell lymphoma. And one of the really important questions was this one – is autologous still relevant? Because, as you know, with the incorporation of CAR T-cell therapy in second line in these patients, the role of autotransplant has been questioned...
So in this last EBMT, we had a really interesting educational session focusing on the current role of transplant in large B-cell lymphoma. And one of the really important questions was this one – is autologous still relevant? Because, as you know, with the incorporation of CAR T-cell therapy in second line in these patients, the role of autotransplant has been questioned. So we presented our results in our Spanish multicenter study, and we confirmed that even if the patient is refractory or has an early relapse, the autotransplant could still play a role. However, we know and we have two phase three clinical trials that have confirmed the superiority of CAR T-cell comparing with autotransplant. But the reality is that so many countries in the world, they don’t have, unfortunately, access to CAR T-cell therapy in second line in this group of patients. So autologous is still really important in some countries. And the main message that we gave in our educational was that if the patient achieved chemosensitivity, autotransplant could still play a really important role and could be a curative option for these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
